These LHRH receptors are not expressed significantly in normal organs, therefore LHRH can act as a targeting ligand to improve the cellular uptake of anticancer drugs to LHRH receptor-positive cancerous cells like breast cancer cells and reduce the peripheral side effects [115]. Here, GNRH1 is linked to breast carcinoma.